These trials completed more than 12 months ago and should have reported results. Some have, some have not.

These trials are not yet due to report results: some are ongoing, some completed within the past 12 months.

These trials have problematic data on the registry. Details why »

Status Trial ID Title Completion date Category
Not reported 2005-002597-30 Placebokontrollierte Untersuchung zur Wirkung von Nikotinsäure auf die Dyslipidämie bei Metabolischem Syndrom und das Arterioskleroserisiko 2008-10-20 due-trials
Reported results 2008-006860-12 Comparative investigation of Insuline glargine versus Metformin as first line drug in treat-ment of early Type 2 Diabetes (GLORY) 2011-08-01 due-trials
Reported results Terminated 2010-021018-49 Fish OIL optimal dosE Determination Study Findungsstudie für die Optimaldosierung von Fischöl 2017-12-15 due-trials
Reported results Terminated 2010-023426-20 Low dose Urokinase therapy in patients with diabetic foot syndrome, critical limb ischemia as well as rest ischemia or missing of option revascularisation in comparison to the standard therapy - rando... 2012-11-22 due-trials
Reported results 2011-005158-73 Superficial vein thrombosis (SVT) treated for forty-five days with Rivaroxaban versus Fondaparinux 2016-05-18 due-trials
Completed, but no date, and reported results 2011-005224-18 Intravenous Ferric Carboxymaltose for improvement of metabolic parameters and vascular function in T2DM patients with iron deficiency bad-data
Completed, but no date, and reported results 2013-003056-21 Evaluation of an additional therapeutic approach to diabetic macular edema by combining standard therapy (intravitreal injection of a VEGF‐inhibitor) with micropulse diode laser treatment in a randomi... bad-data
Reported results 2014-000936-40 pilot study to investigate the effect of e.-coli-nissle as probiotic adjuvant to antidiabetic standard care in patients with diabetic mellitus type 2 Pilotstudie zur Untersuchung der Wirkung von E.... 2015-12-15 due-trials
Reported results 2014-001305-41 MICROVASCULAR AND ANTIINFLAMMATORY EFFECTS OF RIVAROXABAN COMPARED TO LOW DOSE ASPIRIN IN TYPE 2 DIABETIC PATIENTS WITH VERY HIGH CARDIOVASCULAR RISK AND SUBCLINICAL INFLAMMATION Mikrovaskuläre und... 2018-12-12 due-trials
Completed, report not yet due 2014-001757-16 Pomalidomide, ixazomib, and dexamethasone (PId) with or without intensification by cyclophosphamide (PICd): A phase II study in relapsed or refractory multiple myeloma 2024-04-22 not-yet-due
Reported results Terminated 2014-003792-34 RANDOMIZED DOUBLE BLIND PARALLEL DESIGN STUDY COMPARING RISK OF NOCTURNAL HYPOGLYCEMIA AND CRITICAL ARRHYTHMIAS WITH SITAGLIPTIN VERSUS GLIMEPIRIDE IN PATIENTS WITH TYPE 2 DIABETES INSUFFICIENTLY CONT... 2017-01-16 due-trials
Ongoing 2015-002699-26 Pilot study of tolerability and effectivity following application of two combination topical acne products clindamycin 1% and 0.025% tretinoin gel (Acnatac® Gel), adapalen 0,1% and benzoyl peroxide 2,... not-yet-due
Reported results 2016-000327-10 SINGLE AGENT JNJ-56022473 IN MDS AND AML PATIENTS FAILING HYPOMETHYLATING AGENT BASED THERAPY Etude de phase II avec JNJ-56022473 en monothérapie chez les patients présentant un syndrome myélodyspl... 2019-07-15 due-trials
Reported results 2016-000618-30 Phase 2 Clinical Trial with Ponatinib as a Second Line Therapy for Patients with Chronic Myeloid Leukemia in Chronic Phase Resistant or Intolerant to prior First Line Tyrosine Kinase Inhibitor Treatme... 2023-06-22 due-trials
Reported results 2016-005181-57 A randomized, placebo-controlled, double-blind study to scrutinize the efficacy of Secukinumab in patients with moderate to severe atopic dermatitis Randomisierte, Placebo-kontrollierte Doppelblin... 2020-05-04 due-trials
Exempt 2017-001625-40 A MULTICENTER, PHASE I/II STUDY OF SEQUENTIAL EPIGENETIC AND IMMUNE TARGETING IN COMBINATION WITH NAB-PACLITAXEL/GEMCITABINE IN PATIENTS WITH ADVANCED PANCREATIC DUCTAL ADENOCARCINOMA 2024-07-02 not-yet-due
Completed, but no date, and reported results Terminated 2017-003382-10 Quality of life in patients with non-adipocyte soft tissue sarcoma under palliative chemotherapy or pazopanib – a randomized, controlled trial- PazoQoL Lebensqualität bei Patienten mit nicht-adipoz... bad-data
Other 2018-002430-21 Primary comparison of Liposomal Anthracycline based treatment versus conventional care strategies prior to allogeneic stem cell transplantation in patients with higher risk MDS and oligoblastic AML not-yet-due
Other 2019-002962-10 An open-label, prospective Phase III clinical study to compare polatuzumab vedotin plus rituximab, ifosfamide, carboplatin and etoposide (Pola-R-ICE) with rituximab, ifosfamide, carboplatin and etopos... not-yet-due
Reported results 2019-004430-42 Emicizumab in Patients with Acquired Hemophilia A: Multicenter, Single-Arm, Open-Label Clinical Trial 2023-01-04 due-trials
Other 2020-004899-18 A phase IIIb, open-label, single arm study to evaluate the efficacy and safety of luspatercept in patients with lower-risk MDS and ring-sideroblastic phenotype (MDS-RS) not-yet-due